Enbrel - Indications & Dosage

(Page 5)

5. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27(4):361-8.

6. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis.

Arthritis Rheum 2001;44(8):1876-86.

7. Van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531.

8. Arnason BGW, et al. (Lenercept Multiple Sclerosis Study Group). TNF neutralization in MS:Results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457.

9. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334(26):1697.

10. National Cancer Institute. Surveillance, Epidemiology, and End Results Database (SEER) Program. SEER Incidence Crude Rates, 11 Registries, 1992-1999.

11. Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid Arthritis and Cancer Risk. European Journal of Cancer 1996;32A(10):1753-1757.

12. Baecklund E, Ekbom A, Sparen P, et al. Disease Activity and Risk of Lymphoma in Patients With Rheumatoid Arthritis: Nested Case-Control Study. BMJ 1998;317: 180-181.

Manufactured by:

Immunex Corporation

Thousand Oaks, CA 91320-1799

U.S. License Number 1132

Marketed by Amgen and Wyeth Pharmaceuticals

© 2004 Immunex Corporation. All rights reserved.

Issue Date: 09/27/2004

Immunex U.S. Patent Numbers:

5,395,760; 5,605,690; 5,945,397; 6,201,105; 6,572,852; Re. 36,755

ENBREL®

(etanercept)

Single-Use Prefilled Syringe